Galmed Pharma (GLMD) Reports In-Line Q4 EPS

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.30), in-line with the analyst estimate of ($0.30).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Abitibi Metals names new CFO, halts drilling on Quebec fire order
• Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won